Results 71 to 80 of about 6,192 (194)

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

, 2013
CY Pan,1 XL Wang21Chinese PLA General Hospital, Beijing, People's Republic of China; 2Medical Affairs Department, Beijing Novartis Pharma Co, Ltd, Beijing, People's Republic of ChinaAbstract: Vildagliptin is a selective and potent dipeptidyl ...
Wang XL, Pan CY
core  

Drug evaluation: Vildagliptin-metformin single-tablet combination

, 2009
The single-tablet combination of vildagliptin and metformin addresses key defects of type 2 diabetes for improved glycemic control. By inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, vildagliptin raises the levels of the active incretin hormones ...
Piya, Milan K, Piya, Milan, Piya, Milan K. (R19111), Barnett, Anthony, Barnett, Anthony H., Tahrani, Abd A., Tahrani, Abd; id_orcid, Barnett, Anthony H, Tahrani, Abd A   +8 more
core   +1 more source

A case of bullous pemphigoid nduced by vildagliptin

, 2017
Bullous pemfigoid (BP), an autoimmune disorder, can also be induced by some medications. Vildagliptin is a new drug used to treat diabetes mellitus (DM). Recently, a few cases of vildagliptin-induced BP have been described in the literature.
Tas-Aygar, Gamze, Keseroglu, Havva Ozge, GÖKÖZ, ÖZAY, Gonul, Muzeyyen, Ersoy-Evans, Sibel   +4 more
core   +1 more source

Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review

International Journal of Diabetes and Technology
Type 2 diabetes mellitus (T2DM) is a complex disease with multiple pathophysiological defects and generally requires a combination of antidiabetic agents to achieve glycemic targets. In this context, a fixed-dose combination (FDC) of dipeptidyl peptidase-
Subhajyoti Ghosh, Mainak Mukhopadhyay, Mayur Agrawal, Mohammad Shahid, Mahak Lamba, Sudeep Jain, Ashish Prasad, Amit Gupta, Rohan Kesarkar, Sona Warrier, Abhijeet Pednekar   +10 more
doaj   +1 more source

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes. [PDF]

, 2009
Context: Dipeptidyl peptidase-4 (DPP-4) inhibitors act by increasing plasma levels of glucagon-like peptide-1 (GLP-1) and suppressing excessive glucagon secretion in patients with type 2 diabetes (T2DM). However, their effects on the glucagon response to
Persson, Margaretha,, Nilsson, Peter,, Dejager, Sylvie, Nilsson, Peter, Persson, Margaretha, Lund University., Ahrén, Bo, Dunning, Beth E, Foley, James E, Schweizer, Anja, Ahrén, Bo,   +10 more
core   +1 more source

Myocardial-salvaging Effects of a Novel Polyherbal Combination with Dipeptidyl Peptidase-4 Inhibitory Activity

Nigerian Postgraduate Medical Journal
Background: Some of the medicinal plants possess dipeptidyl peptidase-4 (DPP-4) inhibitory properties and could overcome the limitations of synthetic DPP-4 inhibitors.
Devkumar Durgaprasad Tiwari, Ipseeta Ray Mohanty, Ujwala Maheswari, Prithviraj M. Erande, Vandana M Thorat, Aneesa B. Sayed   +5 more
doaj   +1 more source

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus

Сахарный диабет, 2013
According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic ...
Gagik Radikovich Galstyan
doaj   +1 more source

Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

, 2013
AimTo assess whether there is a difference in the effects of vildagliptin and glimepiride on glucose fluctuation in patients with type 2 diabetes mellitus (T2DM) using continuous glucose monitoring (CGM).MethodsThis was an open-label, randomized cross ...
Neelakantham, S, Kulmatycki, K, He, YL, Mattapalli, D, Foteinos, G, Forst, T, Taylor, A   +6 more
core  

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

Diabetes, Metabolic Syndrome and Obesity, 2013
Eleonora Russo, Giuseppe Penno, Stefano Del Prato Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of Pisa, Pisa, Italy Background: Dipeptidyl peptidase-
Russo E, Penno G, Del Prato S
doaj